| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
56.72
|
|
2
|
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
41.47
|
|
3
|
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
26.95
|
|
4
|
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
11.32
|
|
5
|
Achieving standardised reporting of suicide in Australia: rationale and program for change.
|
Med J Aust
|
2010
|
1.78
|
|
6
|
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
|
Neuropharmacology
|
2005
|
1.48
|
|
7
|
Modelling the population-level impact of tai-chi on falls and fall-related injury among community-dwelling older people.
|
Inj Prev
|
2010
|
1.48
|
|
8
|
Return to Work and Functional Outcomes After Major Trauma: Who Recovers, When, and How Well?
|
Ann Surg
|
2016
|
1.42
|
|
9
|
N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.
|
J Pharmacol Exp Ther
|
2003
|
1.32
|
|
10
|
Availability and quality of cause-of-death data for estimating the global burden of injuries.
|
Bull World Health Organ
|
2010
|
1.18
|
|
11
|
Measuring the population burden of fatal and nonfatal injury.
|
Epidemiol Rev
|
2011
|
1.12
|
|
12
|
A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
|
Eur J Pharmacol
|
2005
|
1.12
|
|
13
|
Prevalence and patterns of alcohol use in the Australian workforce: findings from the 2001 National Drug Strategy Household Survey.
|
Addiction
|
2007
|
1.04
|
|
14
|
Workers' drinking patterns: the impact on absenteeism in the Australian work-place.
|
Addiction
|
2008
|
1.00
|
|
15
|
Appearances may deceive: what's going on with Australian suicide statistics?
|
Med J Aust
|
2010
|
0.99
|
|
16
|
Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models.
|
Brain Res
|
2009
|
0.97
|
|
17
|
Cervical spinal cord injury in rugby union and rugby league: are incidence rates declining in NSW?
|
Aust N Z J Public Health
|
2006
|
0.89
|
|
18
|
Self-injury in Australia: a community survey.
|
Med J Aust
|
2010
|
0.89
|
|
19
|
The global injury mortality data collection of the Global Burden of Disease Injury Expert Group: a publicly accessible research tool.
|
Int J Inj Contr Saf Promot
|
2011
|
0.87
|
|
20
|
Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors.
|
Neuropharmacology
|
2010
|
0.86
|
|
21
|
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
|
J Med Chem
|
2010
|
0.86
|
|
22
|
Estimating the cost of alcohol-related absenteeism in the Australian workforce: The importance of consumption patterns.
|
Med J Aust
|
2006
|
0.86
|
|
23
|
The role of design issues in work-related fatal injury in Australia.
|
J Safety Res
|
2008
|
0.85
|
|
24
|
Comparison of measures of comorbidity for predicting disability 12-months post-injury.
|
BMC Health Serv Res
|
2013
|
0.85
|
|
25
|
Routine use of administrative data for safety and quality purposes--hospital mortality.
|
Med J Aust
|
2010
|
0.84
|
|
26
|
Classifying external causes of injury: history, current approaches, and future directions.
|
Epidemiol Rev
|
2011
|
0.84
|
|
27
|
Determining policy-relevant formats for the presentation of falls research evidence.
|
Health Policy
|
2009
|
0.82
|
|
28
|
Predicting trauma patient mortality: ICD [or ICD-10-AM] versus AIS based approaches.
|
ANZ J Surg
|
2010
|
0.82
|
|
29
|
Hospitalisation for head injury due to assault among Indigenous and non-Indigenous Australians, July 1999--June 2005.
|
Med J Aust
|
2008
|
0.81
|
|
30
|
Alcohol and drowning in Australia.
|
Inj Control Saf Promot
|
2004
|
0.81
|
|
31
|
Hospital admissions of indigenous and non-indigenous Australians due to interpersonal violence, July 1999 to June 2004.
|
Aust N Z J Public Health
|
2009
|
0.81
|
|
32
|
Head and traumatic brain injuries among Australian children, July 2000-June 2006.
|
Inj Prev
|
2010
|
0.81
|
|
33
|
A discussion of the potential benefits to injury surveillance through inclusion of date of injury in hospitalisation data in New South Wales and Australia.
|
N S W Public Health Bull
|
2007
|
0.80
|
|
34
|
Modelling long term disability following injury: comparison of three approaches for handling multiple injuries.
|
PLoS One
|
2011
|
0.79
|
|
35
|
Epidemiology of basketball and netball injuries that resulted in hospital admission in Australia, 2000-2004.
|
Med J Aust
|
2009
|
0.77
|
|
36
|
Methodological issues associated with collecting sensitive information over the telephone--experience from an Australian non-suicidal self-injury (NSSI) prevalence study.
|
BMC Med Res Methodol
|
2011
|
0.76
|
|
37
|
Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states.
|
J Pharmacol Exp Ther
|
2006
|
0.76
|
|
38
|
Spinal cord injury register for football: already tackled?
|
Med J Aust
|
2005
|
0.75
|
|
39
|
Identifying work related injuries: comparison of methods for interrogating text fields.
|
BMC Med Inform Decis Mak
|
2010
|
0.75
|
|
40
|
The quality of national data on injuries requiring hospitalisation.
|
Med J Aust
|
2006
|
0.75
|
|
41
|
Trends in the incidence of hospitalisation for injuries resulting from non-traffic crashes in New South Wales, July 1998 to June 2007. Comment.
|
Med J Aust
|
2010
|
0.75
|
|
42
|
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
|
J Pharmacol Exp Ther
|
2004
|
0.75
|